Treatment with either 5-aza-2′-deoxycytidine or trichostatin A, a histone deacetylase inhibitor, markedly enhances the expression of WWOX mRNA and protein in prostate cancer-derived cells (Figure 3) [23]. Here, WWOX is linked to prostate cancer.